Literature DB >> 33797935

Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.

Lillian R Klug1,2,3, Christopher L Corless1,4, Michael C Heinrich1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33797935      PMCID： PMC8274803          DOI： 10.1200/JCO.20.03245

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  133 in total

1.  The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.

Authors:  Philipp Erben; Juliana Schwaab; Georgia Metzgeroth; Hans-Peter Horny; Mohamad Jawhar; Karl Sotlar; Alice Fabarius; Martina Teichmann; Sven Schneider; Thomas Ernst; Martin C Müller; Michelle Giehl; Alexander Marx; Karin Hartmann; Andreas Hochhaus; Wolf-Karsten Hofmann; Nicholas C P Cross; Andreas Reiter
Journal:  Ann Hematol       Date:  2013-11-27       Impact factor: 3.673

2.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family.

Authors:  P Besmer; J E Murphy; P C George; F H Qiu; P J Bergold; L Lederman; H W Snyder; D Brodeur; E E Zuckerman; W D Hardy
Journal:  Nature       Date:  1986 Apr 3-9       Impact factor: 49.962

3.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Authors:  T Schindler; W Bornmann; P Pellicena; W T Miller; B Clarkson; J Kuriyan
Journal:  Science       Date:  2000-09-15       Impact factor: 47.728

4.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

5.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

6.  Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.

Authors:  D Handolias; A L Hamilton; R Salemi; A Tan; K Moodie; L Kerr; A Dobrovic; G A McArthur
Journal:  Br J Cancer       Date:  2010-04-06       Impact factor: 7.640

7.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

8.  Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.

Authors:  Clifford D Mol; Douglas R Dougan; Thomas R Schneider; Robert J Skene; Michelle L Kraus; Daniel N Scheibe; Gyorgy P Snell; Hua Zou; Bi-Ching Sang; Keith P Wilson
Journal:  J Biol Chem       Date:  2004-04-29       Impact factor: 5.157

9.  Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.

Authors:  Susanne Grunewald; Lillian R Klug; Thomas Mühlenberg; Michael C Heinrich; Sebastian Bauer; Jonas Lategahn; Johanna Falkenhorst; Ajia Town; Christiane Ehrt; Eva Wardelmann; Wolfgang Hartmann; Hans-Ulrich Schildhaus; Juergen Treckmann; Jonathan A Fletcher; Sascha Jung; Paul Czodrowski; Stephen Miller; Oleg Schmidt-Kittler; Daniel Rauh
Journal:  Cancer Discov       Date:  2020-09-24       Impact factor: 39.397

Review 10.  KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.

Authors:  M Arock; K Sotlar; C Akin; S Broesby-Olsen; G Hoermann; L Escribano; T K Kristensen; H C Kluin-Nelemans; O Hermine; P Dubreuil; W R Sperr; K Hartmann; J Gotlib; N C P Cross; T Haferlach; A Garcia-Montero; A Orfao; J Schwaab; M Triggiani; H-P Horny; D D Metcalfe; A Reiter; P Valent
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528
View more
  2 in total

Review 1.  New treatment strategies for advanced-stage gastrointestinal stromal tumours.

Authors:  Lillian R Klug; Homma M Khosroyani; Jason D Kent; Michael C Heinrich
Journal:  Nat Rev Clin Oncol       Date:  2022-02-25       Impact factor: 66.675

Review 2.  Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.

Authors:  Seiichiro Katagiri; SungGi Chi; Yosuke Minami; Kentaro Fukushima; Hirohiko Shibayama; Naoko Hosono; Takahiro Yamauchi; Takanobu Morishita; Takeshi Kondo; Masamitsu Yanada; Kazuhito Yamamoto; Junya Kuroda; Kensuke Usuki; Daigo Akahane; Akihiko Gotoh
Journal:  Int J Mol Sci       Date:  2022-04-23       Impact factor: 6.208
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.